COMMUNIQUÉS West-GlobeNewswire

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO

09/09/2024 - 14:30

Purchases Signal Leadership Confidence and Commitment to Company ASHBURN, Va., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage, specialty pharmaceutical company focused on [...]

Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check

09/09/2024 - 14:30

In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage [...]

September 2024 Letter to Shareholders

09/09/2024 - 14:30

VANCOUVER, Washington, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, It continues to be a transformative year for CytoDyn Inc. (“CytoDyn” or the “Company”). A year in which we have made significant strides as a [...]

Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress

09/09/2024 - 14:30

Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal onset seizures VANCOUVER, British Columbia and BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals [...]

Intelligent Bio Solutions Inc. Announces Preliminary Full Fiscal Year 2024 Revenue Growth of 148% Year-Over-Year

09/09/2024 - 14:30

- 2024 unaudited revenue growth for the fiscal fourth quarter and full year of approximately 64% and 148% year-over-year, respectively - NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. ( [...]

Cassava Sciences Names Rick Barry as Chief Executive Officer

09/09/2024 - 14:30

Claude Nicaise, M.D. appointed Chairman of the Board AUSTIN, Texas, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced it [...]

IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

09/09/2024 - 14:30

September 18 th Event in New York City to Include a Review of the Opportunity for Investigational Therapy IMNN-001 (IL-12) to Treat Advanced Ovarian Cancer and Clinical Development Timeline LAWRENCEVILLE, N.J., Sept. 09 [...]

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

09/09/2024 - 14:15

WARREN, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' [...]

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

09/09/2024 - 14:05

TARA-002 demonstrated compelling efficacy and was generally well-tolerated Enrollment in additional cohorts underway with initial results expected in 1H’25 NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Protara [...]

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

09/09/2024 - 14:01

MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor [...]

Creyon Bio Appoints Venture Capitalists Serge Messerlian and Shaquille Vayda to Board of Directors

09/09/2024 - 14:00

SAN DIEGO and RESEARCH TRIANGLE PARK, N.C., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Creyon Bio , Inc. ("Creyon"), a clinical-stage leader in AI/machine learning-enabled engineering of oligonucleotide-based medicines (OBMs), [...]

PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024

09/09/2024 - 14:00

Presentation of data will take place on Saturday, September 14, 2024 PRINCETON, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage [...]

Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer

09/09/2024 - 14:00

BOSTON, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]

Sauce Essentials Transitions to 1.25g All-In-One Vapes in California, Bringing Consumers More Value for the Same Price

09/09/2024 - 14:00

COSTA MESA, CA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Sauce Essentials (“Sauce” or “the Company”), one of the fastest growing US premium cannabis brands committed to providing top-quality products at affordable prices, is [...]

Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma

09/09/2024 - 14:00

Elraglusib Demonstrated Anti-Tumor Activity with Two Ongoing Durable Complete Responses and ~62% Disease Control Rate in First 8 Patients with Relapsed/Refractory Ewing and Ewing-related Sarcomas Enrollment Ongoing with [...]

Excision BioTherapeutics Announces Oral Presentation at the 2024 International HBV Meeting

09/09/2024 - 14:00

SAN FRANCISCO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral [...]

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

09/09/2024 - 14:00

78% of patients dependent on parenteral support were choline deficient, with 63% of these patients demonstrating liver dysfunction, including steatosis, cholestasis, and hepatobiliary injury IV Choline Chloride could [...]

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

09/09/2024 - 14:00

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first [...]

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

09/09/2024 - 14:00

BASKING RIDGE, N.J. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of [...]